Arthropathy of KneePhase 3NCT03133481
Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty
A Phase 3 study testing Adductor Canal Nerve Block and Femoral Nerve Block in people with Arthropathy of Knee, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
Peripheral nerve blocks catheters of the femoral nerve have long been used for perioperative analgesia in total knee arthroplasty (TKA). These blocks provide effective analgesia and patient satisfaction for surgical pain relief. Read more about this study
- Who is it for?
- Ages 19 to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Arthropathy of Knee
- What is being tested?
- Adductor Canal Nerve Block and Femoral Nerve Block
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 94 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Oct 2014to Jan 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 100 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patient undergoing total knee arthroplasty with regional anesthesia planned for postoperative analgesia.
- Adult, 19 years of age or older
- Patient classified as American Society of Anesthesiology (ASA) class I, II, or III
Who cannot join
- Any subject not classified as an ASA I, II, or III
- Allergy/intolerance to local anesthetic
- Pre-existing neurologic or anatomic deficit in lower extremity on the side of the surgical site
- Coexisting coagulopathy such as hemophilia or von Willebrand disease
Trial locations and contacts
1 site in 1 country.
United States1 site
UAB Department of Anesthesiology and Perioperative Medicine
Birmingham, Alabama, 35249
About this study
Peripheral nerve blocks catheters of the femoral nerve have long been used for perioperative analgesia in total knee arthroplasty (TKA). These blocks provide effective analgesia and patient satisfaction for surgical pain relief. However, one of the main drawbacks to the femoral nerve block (FNB) is a denser motor block of the quadriceps muscle that can delay aggressive physical therapy and subsequent recovery from surgery. (1) Recently, there has been increasing interest in performing adductor canal blocks (ACB) with the aim of less motor blockade while providing commensurate analgesia compared to the FNB. (1,2) Current investigative reports have provided only preliminary data, and there is potential to change the standard of care for TKA as more data mounts in favor of ACBs. The goal of this study is to verify the analgesic equivalence of the two blocks, compare patient satisfaction, surgeon satisfaction, and physical therapy grading between the two blocks. Potentially, this would change the standard of care for TKA patients at this institution.
Read the detailed description
The specific objectives of this study are to determine the effectiveness of ACB for analgesia compared to FNB as determined by patient reported VAS scores. Determine the effectiveness of ACB for analgesia compared to FNB as determined by opioid usage. Determine the effectiveness of ACB in physical therapy as determined by early ambulation distance. Determine the surgeon satisfaction via survey, and determine if there is any difference in time to discharge between the two blocks.
Participants in the investigational group will received an adductor canal nerve catheter prior to TKA surgery. Participants in the control group will receive a femoral nerve catheter prior to TKA surgery. After surgery, the patient will be seen in the recovery room to bolus the catheters and start continuous infusions of ropivacaine.
The primary endpoints include, Pain Scores (VAS) at immediate post op, 24 hours, and 48 hours, including highest, opioid consumption at 24 hours and 48 hours pain score at any given time post operatively, physical therapist assessment of patient participation 0-100, distance ambulated at 24 to 48 hours, patient satisfaction, surgeon satisfaction, and hours to discharge.
Participants will be recruited, identified, and interviewed by either the study Principal Investigator or one of the co-investigators. The interviewing investigator will confirm eligibility and the absence of any exclusionary criteria. Details of the study (including risks) will be explained to prospective participants to their satisfaction and consent forms will then be signed.
Randomization: Upon enrollment into the study, participants will be randomized 1:1 to either the investigational group (adductor canal nerve catheter) or the control group (femoral nerve catheter). Randomization will be performed using a random number generator Participants in this study will be randomized into two interventional groups. The participant in the "adductor canal nerve catheter" investigational group will receive an adductor canal block catheter placed under direct ultrasound guidance. The participants in the "femoral nerve catheter" control group will receive a femoral nerve clock catheter placed under direct ultrasound guidance with a stimulating needle. Investigational group participants in the adductor canal block arm will receive an adductor canal block catheter placed under direct ultrasound guidance as follows. Patients will be placed supine with their block limb supinated about 20 degrees to facilitate access to the anteromedial thigh. Standard noninvasive monitors will be applied, and oxygen administered via nasal canula. Parenteral midazolam and fentanyl will be titrated to patient comfort.
Standard skin sterilization, prepping, and draping will be applied to the area. Under ultrasound guidance the needle will be advanced into the adductor canal. After negative aspiration, a bolus of 20 ml 0.5% Ropivacaine will be injected under direct visualization in 5 mL aliquots ensuring proper placement of the needle tip. The catheter will be advanced in this position at least 2 cm and not more than 5 cm and secured to the skin with tegaderm. Patients will be evaluated immediately post-operatively in the PACU (Post anesthesia care unit) to determine VAS score from 0-10.
Patients will be given a standard pain regimen while in the hospital. 24 hour opioid consumption will be calculated. Patients will be evaluated 24 and 48 hours post operatively for VAS score, duration of sensory and motor block, and patient satisfaction from 0-10. The catheter will be removed on post operative day 2. Patient will be followed up until nerve block resolved. Physical therapists in the hospital will be surveyed with a standard questionnaire regarding the patients ability to participate in physical therapy sessions on a scale of 0-10. Ambulation distance at 24 and 48 hours will be recorded per their notes. The surgeons performing the procedures will be surveyed in a general sense regarding their impression of patient recovery with this block. The hours to discharge will be calculated.
Control group participants in the femoral nerve block arm will receive a femoral nerve block catheter placed under direct ultrasound guidance with the stimulating needle as follows. Patients will be placed supine with their block limb exposed to facilitate access to the anterior inguinal area. Standard noninvasive monitors will be applied, and oxygen administered via nasal canula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping, and draping will be applied to the area. Under ultrasound guidance the needle will be advanced to the femoral nerve. After negative aspiration, a bolus of 20 ml 0.5% Ropivacaine will be injected under direct visualization in 5 mL aliquots ensuring proper placement of the needle tip. The catheter will be advanced in this position at least 2 cm and not more than 5 cm and secured to the skin with tegaderm. Patients will be evaluated immediately post-operatively in the PACU (Post anesthesia care unit) to determine VAS score from 0-10.
Physical therapist and physicians will be asked to complete a short survey after their patient has enrolled in the study. A Waiver of Informed Consent is requested for their participation.
Patients will be given a standard pain regimen while in the hospital. 24 hour opioid consumption will be calculated. Patients will be evaluated 24 and 48 hours post operatively for VAS score, duration of sensory and motor block, and patient satisfaction from 0-10. The catheter will be removed on post operative day 2. Patient will be followed up until nerve block resolved. Physical therapists in the hospital will be surveyed with a standard questionnaire regarding the patients ability to participate in physical therapy sessions on a scale of 0-100. Ambulation distance at 24 and 48 hours will be recorded per their notes. The surgeons performing the procedures will be surveyed in a general sense regarding their impression of patient recovery with this block then the hours will be calculated to the hours to discharge for each patient.
All demographic and clinical variables with continuous measures will be expressed as means and standard deviations; categorical factors will be expressed as proportions. For non-normal data, the medians and inter quartile ranges will be displayed. The distribution of the continuous factors will be examined using the Kolmogorov-Smirnov test. For data that are normally distributed, the one-way ANOVA and Student's t-test will be used to compare groups of data. For data that are not normally distributed, the Kruskal-Wallis and Mann-Whitney tests will be used for comparisons. Chi-square and Fisher's exact tests will be used to analyze categorical data. For all comparisons, a value of p < 0.05 will be considered statistically significant.
Primary Outcome Analysis: Statistical analyses will be performed using SAS for Windows, version 9.2. Student's t-test will be used to compare post-operative pain scores for investigational and control subjects. Linear regression will be also be used to test the relationship between pain scores and regional anesthetic technique, while controlling for relevant clinical and demographic variables. Distance of first ambulation will be analyzed using Cox proportional hazards model. Student's t-test will be used to compare patient and surgeon satisfaction.
Statistical Power and Sample Size Estimates: Sample size (94) was determined using a Cohen's d table assuming a mean pain VAS score of 8 (sd = 3) on a scale of 0-10 for control subjects. A sample of 94 participants (45 patients in the adductor canal block group, and 49 patients in the femoral nerve block group) will have approximately 80% power to detect a reduction in pain score of at least 50%, and approximately 99% to detect an 80% reduction in pain score.
- Conditions
- Arthropathy of Knee
- Being tested
- Adductor Canal Nerve Block, Femoral Nerve Block
- Keywords
- Adductor Canal Block, Femoral Canal Block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Adductor Canal Nerve BlockProcedure or surgery
Also called ropivacaine
Adductor Canal never technique
Femoral Nerve BlockDrug
Also called ropivacaine
Traditional technique
| Study group | Role | What they receive |
|---|---|---|
| Adductor Canal Nerve Block | Active comparator | Participants will be randomized using block randomization. Receives: Procedure: Adductor Canal Nerve Block |
| Femoral Nerve Block | Active comparator | Participants will be randomized using block randomization. Receives: Drug: Femoral Nerve Block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Distance Ambulated at 24 Hours Post Operatively
Distance ambulated in feet from the end of surgery to 24 hours postoperatively
Measured: Baseline up to 24 hours after the Anesthesia Record Stop Time
Mean Distance Ambulated at 48 Hours Post Operatively
Distance ambulated in feet from the end of surgery to 48 hours postoperatively
Measured: From the Anesthesia Record Stop Time to 48 hours after the Anesthesia Record Stop Time
Secondary outcomes (10)
Mean Pain Scores Immediately Preoperatively
Visual Analog Scale (VAS) score immediately preoperatively.
The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.
Measured: baseline up to time of anesthesia record start time
Mean Opioid Consumption as Measured by Oral Morphine Milligram Equivalents
Preoperatively, opioid consumption will be measured from baseline to the Anesthesia Record Start Time in Oral Morphine Equivalents
Measured: from baseline to two hours
Patient Satisfaction at 48 Hours Post Operatively
Patient satisfaction score, on an analog scale from 0-10, with 0 being the lowest satisfaction and 10 being the highest satisfaction.
Measured: Baseline up to 48 hrs
Mean Hours to Discharge
Mean hours to discharge, from the time of admittance to the time of discharge
Measured: Baseline to discharge (approximately 90 hrs)
Mean Pain Scores in PACU
The Mean Pain Score (VAS) at no more than 4 hours after the Anesthesia Record Stop Time.
The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.
Measured: Immediately post operatively, not more than 4 hours after pacu admittance
Mean Pain Scores at 24 Hours
Visual Analog Scale (VAS) score at 24 hours from the time of Anesthesia Record Stop Time.
The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.
Measured: From the Anesthesia Record stop time to 24 hours after Anesthesia Record stop time
Mean Pain Scores 48 Hours Postoperatively
Visual Analog Scale (VAS) score at 48 hours from the time of Anesthesia Record Stop Time.
The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.
Measured: From the Anesthesia Record Stop Time to 48 hours from the Anesthesia Record Stop Time
Mean Opioid Consumption as Measured in Oral Morphine Milligram Equivalents
Mean opioid consumption as measured immediately post operatively from Anesthesia Record Stop Time to 4 hours after Anesthesia Record Stop Time in Oral Morphine Milligram Equivalents
Measured: Post operatively through 4 hours
Mean Opioid Consumption as Measured in Oral Morphine Milligram Equivalents
Mean opioid consumption as calculated from the time of Anesthesia Record Stop Time to 24 hours after Anesthesia Record Stop Time in Oral Morphine Equivalents
Measured: From immediately post operatively through 24 hours
Mean Opioid Consumption as Measured in Oral Morphine Equivalents
Mean opioid consumption as calculated from Anesthesia Record Stop Time to 48 hours after Anesthesia Record Stop Time in Oral Morphine Milligram Equivalents
Measured: From immediately post operatively through 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2017
- Study start22 Oct 2014
- Primary completionOct 2017
- Study completionJan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Arthropathy of KneeStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The first two groups will have 50 participants each (100 total) the "Adductor Canal Nerve Catheter" group and the "Femoral Nerve Catheter," group. Participants will be randomized using block randomization. The blocks will be assigned randomly based on computer generated numbers.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 94 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Promil Kukreja, University of Alabama at Birmingham
- Investigators
- Promil Kukreja, MD, Principal investigator, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03133481
- Sponsor's protocol ID
- F140917004
- Status last verified
- Jan 2019
- First submitted
- 14 Apr 2017
- Last updated
- 16 Jan 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty
- ClinicalTrials.gov ID
- NCT03133481
- Acronym / sponsor ID
- F140917004
- Conditions
- Arthropathy of Knee
- Keywords
- Adductor Canal Block, Femoral Canal Block
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 94 participants (actual)
- Lead sponsor
- University of Alabama at BirminghamUniversity, hospital or other
- Study start
- 22 Oct 2014 (actual)
- Primary completion
- Oct 2017 (actual)
- Study completion
- Jan 2019 (actual)
- First posted
- 28 Apr 2017 (actual)
- Results
- Posted 16 Jan 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Peripheral nerve blocks catheters of the femoral nerve have long been used for perioperative analgesia in total knee arthroplasty (TKA). These blocks provide effective analgesia and patient satisfaction for surgical pain relief. However, one of the main drawbacks to the femoral nerve block (FNB) is a denser motor block of the quadriceps muscle that can delay aggressive physical therapy and subsequent recovery from surgery. (1) Recently, there has been increasing interest in performing adductor canal blocks (ACB) with the aim of less motor blockade while providing commensurate analgesia compared to the FNB. (1,2) Current investigative reports have provided only preliminary data, and there is potential to change the standard of care for TKA as more data mounts in favor of ACBs. The goal of this study is to verify the analgesic equivalence of the two blocks, compare patient satisfaction, surgeon satisfaction, and physical therapy grading between the two blocks. Potentially, this would change the standard of care for TKA patients at this institution.
Detailed description
The specific objectives of this study are to determine the effectiveness of ACB for analgesia compared to FNB as determined by patient reported VAS scores. Determine the effectiveness of ACB for analgesia compared to FNB as determined by opioid usage. Determine the effectiveness of ACB in physical therapy as determined by early ambulation distance. Determine the surgeon satisfaction via survey, and determine if there is any difference in time to discharge between the two blocks.
Participants in the investigational group will received an adductor canal nerve catheter prior to TKA surgery. Participants in the control group will receive a femoral nerve catheter prior to TKA surgery. After surgery, the patient will be seen in the recovery room to bolus the catheters and start continuous infusions of ropivacaine.
The primary endpoints include, Pain Scores (VAS) at immediate post op, 24 hours, and 48 hours, including highest, opioid consumption at 24 hours and 48 hours pain score at any given time post operatively, physical therapist assessment of patient participation 0-100, distance ambulated at 24 to 48 hours, patient satisfaction, surgeon satisfaction, and hours to discharge.
Participants will be recruited, identified, and interviewed by either the study Principal Investigator or one of the co-investigators. The interviewing investigator will confirm eligibility and the absence of any exclusionary criteria. Details of the study (including risks) will be explained to prospective participants to their satisfaction and consent forms will then be signed.
Randomization: Upon enrollment into the study, participants will be randomized 1:1 to either the investigational group (adductor canal nerve catheter) or the control group (femoral nerve catheter). Randomization will be performed using a random number generator Participants in this study will be randomized into two interventional groups. The participant in the "adductor canal nerve catheter" investigational group will receive an adductor canal block catheter placed under direct ultrasound guidance. The participants in the "femoral nerve catheter" control group will receive a femoral nerve clock catheter placed under direct ultrasound guidance with a stimulating needle. Investigational group participants in the adductor canal block arm will receive an adductor canal block catheter placed under direct ultrasound guidance as follows. Patients will be placed supine with their block limb supinated about 20 degrees to facilitate access to the anteromedial thigh. Standard noninvasive monitors will be applied, and oxygen administered via nasal canula. Parenteral midazolam and fentanyl will be titrated to patient comfort.
Standard skin sterilization, prepping, and draping will be applied to the area. Under ultrasound guidance the needle will be advanced into the adductor canal. After negative aspiration, a bolus of 20 ml 0.5% Ropivacaine will be injected under direct visualization in 5 mL aliquots ensuring proper placement of the needle tip. The catheter will be advanced in this position at least 2 cm and not more than 5 cm and secured to the skin with tegaderm. Patients will be evaluated immediately post-operatively in the PACU (Post anesthesia care unit) to determine VAS score from 0-10.
Patients will be given a standard pain regimen while in the hospital. 24 hour opioid consumption will be calculated. Patients will be evaluated 24 and 48 hours post operatively for VAS score, duration of sensory and motor block, and patient satisfaction from 0-10. The catheter will be removed on post operative day 2. Patient will be followed up until nerve block resolved. Physical therapists in the hospital will be surveyed with a standard questionnaire regarding the patients ability to participate in physical therapy sessions on a scale of 0-10. Ambulation distance at 24 and 48 hours will be recorded per their notes. The surgeons performing the procedures will be surveyed in a general sense regarding their impression of patient recovery with this block. The hours to discharge will be calculated.
Control group participants in the femoral nerve block arm will receive a femoral nerve block catheter placed under direct ultrasound guidance with the stimulating needle as follows. Patients will be placed supine with their block limb exposed to facilitate access to the anterior inguinal area. Standard noninvasive monitors will be applied, and oxygen administered via nasal canula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping, and draping will be applied to the area. Under ultrasound guidance the needle will be advanced to the femoral nerve. After negative aspiration, a bolus of 20 ml 0.5% Ropivacaine will be injected under direct visualization in 5 mL aliquots ensuring proper placement of the needle tip. The catheter will be advanced in this position at least 2 cm and not more than 5 cm and secured to the skin with tegaderm. Patients will be evaluated immediately post-operatively in the PACU (Post anesthesia care unit) to determine VAS score from 0-10.
Physical therapist and physicians will be asked to complete a short survey after their patient has enrolled in the study. A Waiver of Informed Consent is requested for their participation.
Patients will be given a standard pain regimen while in the hospital. 24 hour opioid consumption will be calculated. Patients will be evaluated 24 and 48 hours post operatively for VAS score, duration of sensory and motor block, and patient satisfaction from 0-10. The catheter will be removed on post operative day 2. Patient will be followed up until nerve block resolved. Physical therapists in the hospital will be surveyed with a standard questionnaire regarding the patients ability to participate in physical therapy sessions on a scale of 0-100. Ambulation distance at 24 and 48 hours will be recorded per their notes. The surgeons performing the procedures will be surveyed in a general sense regarding their impression of patient recovery with this block then the hours will be calculated to the hours to discharge for each patient.
All demographic and clinical variables with continuous measures will be expressed as means and standard deviations; categorical factors will be expressed as proportions. For non-normal data, the medians and inter quartile ranges will be displayed. The distribution of the continuous factors will be examined using the Kolmogorov-Smirnov test. For data that are normally distributed, the one-way ANOVA and Student's t-test will be used to compare groups of data. For data that are not normally distributed, the Kruskal-Wallis and Mann-Whitney tests will be used for comparisons. Chi-square and Fisher's exact tests will be used to analyze categorical data. For all comparisons, a value of p < 0.05 will be considered statistically significant.
Primary Outcome Analysis: Statistical analyses will be performed using SAS for Windows, version 9.2. Student's t-test will be used to compare post-operative pain scores for investigational and control subjects. Linear regression will be also be used to test the relationship between pain scores and regional anesthetic technique, while controlling for relevant clinical and demographic variables. Distance of first ambulation will be analyzed using Cox proportional hazards model. Student's t-test will be used to compare patient and surgeon satisfaction.
Statistical Power and Sample Size Estimates: Sample size (94) was determined using a Cohen's d table assuming a mean pain VAS score of 8 (sd = 3) on a scale of 0-10 for control subjects. A sample of 94 participants (45 patients in the adductor canal block group, and 49 patients in the femoral nerve block group) will have approximately 80% power to detect a reduction in pain score of at least 50%, and approximately 99% to detect an 80% reduction in pain score.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- The first two groups will have 50 participants each (100 total) the "Adductor Canal Nerve Catheter" group and the "Femoral Nerve Catheter," group. Participants will be randomized using block randomization. The blocks will be assigned randomly based on computer generated numbers.
| Arm | Type | Receives |
|---|---|---|
| Adductor Canal Nerve Block | Active comparator | Procedure: Adductor Canal Nerve BlockParticipants will be randomized using block randomization. |
| Femoral Nerve Block | Active comparator | Drug: Femoral Nerve BlockParticipants will be randomized using block randomization. |
Who may qualify
- Ages
- 19 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patient undergoing total knee arthroplasty with regional anesthesia planned for postoperative analgesia.
- Adult, 19 years of age or older
- Patient classified as American Society of Anesthesiology (ASA) class I, II, or III
Key exclusion criteria (4 listed)
- Any subject not classified as an ASA I, II, or III
- Allergy/intolerance to local anesthetic
- Pre-existing neurologic or anatomic deficit in lower extremity on the side of the surgical site
- Coexisting coagulopathy such as hemophilia or von Willebrand disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Adductor Canal Nerve BlockAlso: ropivacaineAdductor Canal never technique | Procedure or surgery | Adductor Canal Nerve Block |
| Femoral Nerve BlockAlso: ropivacaineTraditional technique | Drug | Femoral Nerve Block |
Primary outcome
Mean Distance Ambulated at 24 Hours Post Operatively
Time frame: Baseline up to 24 hours after the Anesthesia Record Stop Time
Distance ambulated in feet from the end of surgery to 24 hours postoperatively
Mean Distance Ambulated at 48 Hours Post Operatively
Time frame: From the Anesthesia Record Stop Time to 48 hours after the Anesthesia Record Stop Time
Distance ambulated in feet from the end of surgery to 48 hours postoperatively
10 secondary outcomes
Mean Pain Scores Immediately Preoperatively
Time frame: baseline up to time of anesthesia record start time
Mean Opioid Consumption as Measured by Oral Morphine Milligram Equivalents
Time frame: from baseline to two hours
Patient Satisfaction at 48 Hours Post Operatively
Time frame: Baseline up to 48 hrs
Mean Hours to Discharge
Time frame: Baseline to discharge (approximately 90 hrs)
Mean Pain Scores in PACU
Time frame: Immediately post operatively, not more than 4 hours after pacu admittance
Mean Pain Scores at 24 Hours
Time frame: From the Anesthesia Record stop time to 24 hours after Anesthesia Record stop time
Mean Pain Scores 48 Hours Postoperatively
Time frame: From the Anesthesia Record Stop Time to 48 hours from the Anesthesia Record Stop Time
Mean Opioid Consumption as Measured in Oral Morphine Milligram Equivalents
Time frame: Post operatively through 4 hours
Mean Opioid Consumption as Measured in Oral Morphine Milligram Equivalents
Time frame: From immediately post operatively through 24 hours
Mean Opioid Consumption as Measured in Oral Morphine Equivalents
Time frame: From immediately post operatively through 48 hours
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Undecided
Related trials for Arthropathy of Knee
Recruiting
Effects of Telerehabilitation Versus Supervised Rehabilitation Protocol on Pain, Range of Motion and Functional Recovery in Patients With Patellofemoral Pain Syndrome.
Patello Femoral Pain Syndrome
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Promil Kukreja, MD principal investigator
University of Alabama at Birmingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Adductor Canal Nerve Block and Femoral Nerve Block in people with Arthropathy of Knee, run by University of Alabama at Birmingham at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Jan 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Distance Ambulated at 24 Hours Post Operatively (time frame: Baseline up to 24 hours after the Anesthesia Record Stop Time). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2019.